Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21784381 | 0.79 | KDM1A (0.56) | EPHX1EPHX2KDM1ACYP2C19PARP1 | |
| SCHEMBL11942148 | 0.78 | EPHX1 (0.53) | EPHX1EPHX2KDM1ACYP2C19PARP1 | |
| SCHEMBL4131627 | 0.76 | EPHX1 (0.59) | EPHX1EPHX2KDM1ACYP2C19PARP1 | |
| SCHEMBL771580 | 0.76 | EPHX2 (0.53) | EPHX1EPHX2KDM1A | |
| SCHEMBL23490137 | 0.75 | EPHX1 (0.57) | EPHX1EPHX2KDM1ACYP2C19PARP1 | |
| SCHEMBL3581538 | 0.75 | EPHX1 (0.50) | EPHX1EPHX2KDM1ACYP2C19PARP1 | |
| Trifluoroacetic Acid SCHEMBL4513278 | 0.74 | EPHX1 (0.49) | EPHX1EPHX2KDM1ACYP2C19PARP1 | |
| SCHEMBL4140326 | 0.73 | EPHX1 (0.46) | EPHX1EPHX2KDM1ACYP2C19PARP1 | |
| SCHEMBL770648 | 0.73 | EPHX1 (0.47) | EPHX1EPHX2ALDH1A1 | |
| SCHEMBL5758149 | 0.72 | EPHX1 (0.46) | EPHX1EPHX2KDM1ARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | claimed |
| EP-2049548-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | claimed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | claimed |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| EP-2049548-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | HRH3, HRH4, HRH2 | EPHX1 845/4885EPHX2 477/4885KDM1A 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.